| Clinical data | |
|---|---|
| Other names | Dimethylaminopyrazine; W-3580B; W3580-B; W-3580-B; W3580B |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C6H9N3 |
| Molar mass | 123.159 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ampyzine (INNTooltip International Nonproprietary Name), also known as dimethylaminopyrazine or as ampyzine sulfate (USANTooltip United States Adopted Name) in the case of the sulfate salt (developmental code name W-3580B), is a drug described as a "central stimulant" or "CNS stimulant" and "euphoriant". It is said to be a monoamine oxidase inhibitor (MAOI). Ampyzine was first described in the scientific literature by 1960.
An analogue of ampyzine is triampyzine (3,5,6-trimethylampyzine; developmental code name W-3976B). This drug is described as an anticholinergic and antisecretory agent.
The classical method for synthesizing 2-aminopyrazines is illustrated by the synthesis of ampyzine. The condensation reaction between glyoxal and 2-aminomalonamide forms the pyrazine derivative (1). Acid-catalysed hydrolysis of the amide and decarboxylation gives 2-hydroxypyrazine (3). Halogenation with phosphorus pentachloride produces 2-chloropyrazine (4) which reacts with dimethylamine to yield ampyzine.